TY -非盟的刘MingXin盟——周,思玉盟——金、群盟——西村Shoji盟————Atsushi PY - 2022 DA - 2022/10/27 TI -有效性,政策,和用户接受COVID-19 Post-COVID-19大流行时期接触者追踪应用:经验和比较研究乔- JMIR公共卫生Surveill SP - e40233六世- 8 - 10 KW - COVID-19千瓦接触者追踪应用KW -数字接触者追踪KW -手机AB -背景:在新冠肺炎大流行后的时代，许多国家都推出了追踪新冠肺炎接触者的app。由于各国联系人追踪政策或技术的不同，每个联系人追踪app都面临着各种各样的问题。目的:本研究旨在调查世界各国用于追踪接触者的CTA软件，包括每个CTA软件使用的技术、官方网站获取CTA相关知识的情况、各国CTA软件的互操作性、CTA软件启动国的感染检出率和政策，并根据收集到的信息总结当前CTA软件存在的问题。方法:我们调查了通过谷歌、谷歌Scholar和PubMed在所有国家推出的cta。我们对所有可以安装的应用程序进行了实验，并通过查阅官方网站和以前的文献，收集了不能安装或使用的应用程序的信息。我们将收集到的cta信息与之前的相关文献进行比较，以了解和分析数据。结果:在筛选了全球197个国家开发的166个COVID-19应用程序后，我们从95个国家(48.2%)选择了98个(59%)应用程序，其中63个(66.3%)应用程序可用。联系人追踪的方法主要分为三大类:蓝牙、地理定位和二维码。在技术层面，cta面临三个主要问题。 First, the distance and time for Bluetooth- and geolocation-based CTAs to record contact are generally set to 2 meters and 15 minutes; however, this distance should be lengthened, and the time should be shortened for more infectious variants. Second, Bluetooth- or geolocation-based CTAs also face the problem of lack of accuracy. For example, individuals in 2 adjacent vehicles during traffic jams may be at a distance of ≤2 meters to make the CTA trace contact, but the 2 users may actually be separated by car doors, which could prevent transmission and infection. In addition, we investigated infection detection rates in 33 countries, 16 (48.5%) of which had significantly low infection detection rates, wherein CTAs could have lacked effectiveness in reducing virus propagation. Regarding policy, CTAs in most countries can only be used in their own countries and lack interoperability among other countries. In addition, 7 countries have already discontinued CTAs, but we believe that it was too early to discontinue them. Regarding user acceptance, 28.6% (28/98) of CTAs had no official source of information that could reduce user acceptance. Conclusions: We surveyed all CTAs worldwide, identified their technological policy and acceptance issues, and provided solutions for each of the issues we identified. This study aimed to provide useful guidance and suggestions for updating the existing CTAs and the subsequent development of new CTAs. SN - 2369-2960 UR - https://publichealth.www.mybigtv.com/2022/10/e40233 UR - https://doi.org/10.2196/40233 UR - http://www.ncbi.nlm.nih.gov/pubmed/36190741 DO - 10.2196/40233 ID - info:doi/10.2196/40233 ER -